Clinical associates

Pablo Martinez, MD, PhD, (Pablo_MartinezRodriguez@dfci.harvard.edu) brings experience with treating patients in the clinical trial setting to his work on clinical data mining to identify patterns that may hint at resistance mechanisms to targeted therapies among ALK- and ROS-positive lung cancer patients. He is also involved in tumor/plasma genotyping and identifying better therapeutic strategies to overcome resistance to ALK and ROS inhibitors.